Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113248 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2ENPEPLTA4HSLC7A5 | |
| SCHEMBL4908053 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2ENPEPLTA4HSLC7A5 | |
| SCHEMBL29493996 | 0.80 | EPHX1 (0.31) | GABRR1PMP22 | |
| SCHEMBL7193017 | 0.77 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HFOLH1 | |
| SCHEMBL8436474 | 0.77 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HFOLH1 | |
| SCHEMBL1601477 | 0.77 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HFOLH1 | |
| SCHEMBL2437343 | 0.77 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HFOLH1 | |
| SCHEMBL4898850 | 0.77 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HFOLH1 | |
| SCHEMBL27431345 | 0.77 | GABRR1 (0.42) | GABRR1CYP1A2ENPEPLTA4HFOLH1 | |
| SCHEMBL14611452 | 0.76 | GABRR1 (0.54) | GABRR1CYP1A2ENPEPLTA4HFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | disclosed |
| US-7091219-B2 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | disclosed |
| US-6569882-B2 | Viricides; enzyme inhibitors | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | disclosed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | disclosed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | disclosed |
| US-6143747-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | GABRR1 2795/4885CYP1A2 2446/4885ENPEP 29/4885 |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | GABRR1 2713/4885CYP1A2 2576/4885ENPEP 19/4885 |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | GABRR1 2795/4885CYP1A2 2446/4885ENPEP 29/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | GABRR1 2713/4885CYP1A2 2576/4885ENPEP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.